SCHEMBL5243170

SCHEMBL5243170

CCOC(=O)c1ccc(-c2ccc(C(=C3C(=O)NNC3=O)c3cccc(C)c3)o2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.50
KDM4E B2RXH2 5/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
ALDH1A1 P00352 4/20 0.50
HPGD P15428 4/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HSP90AA1 P07900 1/20 0.47
MAPK1 P28482 2/20 0.46
USP2 O75604 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 1/20 0.45
TNKS O95271 1/20 0.45
TP53 P04637 3/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147453 0.86 KCNH2 (0.42) MAPTKDM4EALDH1A1HPGDPOLB
SCHEMBL5145164 0.75 KDM4E (0.48) MAPTKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL12877039 0.72 MAPT (0.58) MAPTKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3068729 0.72 MAPT (0.64) MAPTKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL23091176 0.70 MAPT (0.62) MAPTKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL26054645 0.70 MAPT (0.64) MAPTKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL5143187 0.70 CDK2 (0.47) KDM4EALDH1A1POLBTDP1GAA
SCHEMBL29360475 0.69 TDP1 (0.60) NPC1RAB9AALDH1A1HPGDTDP1
SCHEMBL570920 0.69 TDP1 (0.60) NPC1RAB9AALDH1A1HPGDTDP1
SCHEMBL14379380 0.69 MAPT (0.55) MAPTKDM4ESMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MAPT 2096/4885KDM4E 4569/4885SMN1; SMN2 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.